News from AHA 2024: BROOKLYN, obicetrapib, CETPi in HeFH

Stephen Nicholls at AHA

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

AHA exists 100 years: What can we possibly expect in the next century?
AHA exists 100 years: What can we possibly expect in the next century?
AHA 2024
AHA exists 100 years: What can we possibly expect in the next century?
- Keith Churchwell, MD
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
AHA 2024
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
- Subodh Verma, MD, PhD